ArticleScience advances2026
A clinical and experimental investigation of liraglutide effects on the brain-kidney axis.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists elicit diuresis and natriuresis in humans and rodents. However, little is known about their interactions with the bodies hormonal systems that control fluid homeostasis. We performed a single center, open-label, before-and-after study and discovered that liraglutide reduces plasma arginine vasopressin (AVP) levels in healthy humans. By quantitative proteomic and phosphoproteomic investigation of the rat pituitary gland, we detail time- and sex-dependent modifications to synaptic proteins mediated by liraglutide. We developed an in vitro AVP luciferase assay to assess the impact of synaptic protein phosphorylation on AVP secretion. We used this assay to identify synaptic protein phosphosites that influence AVP release and liraglutide-mediated sex differences in AVP release. Investigation of AVP downstream signaling pathways in the kidney revealed posttranslational changes to the crucial AVP-regulated water channel aquaporin 2. Thus, glucagon-like peptide-1 receptor agonist modulation of AVP release may be responsible for cardiovascular and renal changes observed in patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.